On the stock market since 2018, it operates in the world of health and science. It has 25 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 19 buys and 18 sells. Management buying with its own money is usually read as a good sign.
A loss of $178.0M against $0 in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, RENB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RENB is a high-risk stock — not yet profitable, and its future rides on its product catching on.